Comparative Pharmacology
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSFOMYCIN TROMETHAMINE versus MILI.
FOSFOMYCIN TROMETHAMINE vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
3 g orally once as a single dose for uncomplicated urinary tract infection.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category A/B
Category C
Antibiotic
Antibiotic